Preotact

Active Substance: parathyroid hormone (rDNA)
Common Name: parathyroid hormone (rDNA)
ATC Code: H05AA03
Marketing Authorisation Holder: NPS Pharma Holdings Limited
Active Substance: parathyroid hormone (rDNA)
Status: Withdrawn
Authorisation Date: 2006-04-24
Therapeutic Area: Osteoporosis, Postmenopausal
Pharmacotherapeutic Group: Calcium homeostasis

Therapeutic Indication

Treatment of osteoporosis in postmenopausal women at high risk of fractures (see section 5.1).

A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

The marketing authorisation for Preotact has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web3)